TriCares is a medical device company behind Topaz, an innovative device designed specifically to help patients suffering from severe tricuspid regurgitation without the need for open heart surgery. The Topaz device is implanted in a minimally invasive procedure through the patient's femoral vein. It is designed specifically to fit the tricuspid valve anatomy and thus supports ease of positioning and functionality.
27 Avenue de l'Opéra
27 Avenue de l'Opéra
Key people 🧑🤝🧑
- Solving a problem: In the last decade minimally invasive catheterbased solutions have been developed for other valve diseases. However for patients with tricuspid valve disease open-heart surgeries and medical treatment are the current standard treatment options. Owing to high mortality, access to such surgery is severely restricted leaving surgeons seeking minimally-invasive, low-risk solutions to potentially treat patients.
- Important market: Heart valve diseases are among the most serious cardiac conditions affecting more than 12.7 million patients in Europe.
- Patent-protected technology: During the years, TRiCares has filed for a few patents, including those related to the heart valve anchoring device and the delivery apparatus for the self-expanding medical device.
- Global ambitions: TRiCares has been cooperating with hospitals and health systems in Europe and Canada, with the ultimate goal to have the Topaz system available to patients all across the world.
TRiCares' world-class founding medical team and highly qualified development group and management are a great asset in transforming TRiCares' novel approach into an effective product addressing a highly unmet medical need. TRiCares is a perfect match for our investment strategy: high quality European innovation with the potential to yield significant improvements for patients, practitioners and payors, addressing a potentially vast global market with strong strategic interest.
— Dr. Regina Hodits, Managing Partner at Wellington Partners 🔗
TRiCares is among the first to address the transcatheter replacement of the 'forgotten' tricuspid valve. We are excited to accompany TRiCares in the next phases of development of its innovative device for tricuspid regurgitation patients who currently have limited therapeutic options.
— Sofia Ioannidou, Director at Andera Partners 🔗
The Management Team around Helmut Straubinger has developed a convincing new implant system. We are proud to be part of the syndicate that should bring TRiCares to the next value inflection point.
— Thomas Moeller, General Partner at BioMedPartners 🔗
Last update: January 13, 2023
Disclaimer: We can not guarantee that the information on this page is 100% correct. more